Industry Insight
Discovery Technology
Analytical Laboratory Technology
Biopharma
Manufacturing
Delivery Systems
Ingredients, Formulation and Finishing
Bioprocessing
View our other publications with free access to extensive archives

News

 23rd May 2008 Lonza Walkerville

Lonza Group Ltd Muenchensteinerstrasse 38 CH-4002 Basel, Switzerland www.lonza.com

Product News

Lonza introduces microCompassTM TYMC – the second in a series of rapid microbial detection solutions Basel, 02.04.2008 – Lonza, the global life-science company, introduces microCompass™ TYMC Detection Kit - the second in the microCompass™ series and a supplement to the patented breakthrough technology in microbiology testing which was introduced by Lonza last year. microCompass™ TYMC (which stands for Total Yeast and Mold Count) is used for the universal detection of yeast and mold RNA by Real-Time Reverse Transcriptase (RT) PCR, and is the only genetic-based test on the market to quantify yeast and mold. The new kit can produce results in as little as 4 hours compared to the standard method for yeast and mold which can take 3-14 days to produce results. “We are excited to offer this latest innovation in rapid microbial detection solutions. Early indications show customers appreciate the speed and accuracy microCompass™ TYMC provides,” said Shawn Cavanagh, President, Lonza Bioscience. With the introduction of microCompass™ last year, Lonza became the first bioscience company to provide a molecular testing method to attain a viable count of microorganisms in as little as four hours. The microCompass™ system dramatically increased the speed for microbiology testing. microCompass™ TYMC is an exciting new addition. The microCompass™ system offers improved sensitivity and detection of viable organisms without pre-enrichment. The system allows quantitative detection of bacteria, yeast and mold at a high throughput-level by batching up to 96 samples at a time. Quick time to results (TTR) with microCompass™ enables significant labor and cost savings, as well as delivers more rapid product release to the market. These benefits allow for an appreciable increase in client profitability. The microCompass™ system is ideal for applications in personal care products, pharmaceutical raw materials, over-the-counter drugs, nutraceuticals, preservative efficacy test and cell culture. Application laboratories for microCompass™ TYMC are located in Walkersville, MD (USA) and in Saint Beauzire (France). Information on this breakthrough technology in microbiology testing can be found on www.lonza.com/microcompass. Customers with questions are encouraged to contact Deborah Thompson, Sr. Product Manager, Lonza at (301) 898-7025 x2414. About Lonza Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets. Lonza is headquartered in Basel, Switzerland and is listed on the SWX Swiss Exchange. In 2007, Lonza had sales of CHF 2.87 billion. Further information can be found at: www.lonza.com.

For further Information:

Head Corporate Communications Janet White Tel +41 61 316 8566 Fax +41 61 316 9566 janet.white@lonza.com

Media Relations Dominik Werner Tel +41 61 316 8798 Fax +41 61 316 9798 dominik.werner@lonza.com

Investor Relations Alexandre Pasini Tel +41 61 316 8835 Fax +41 61 316 9835 alexandre.pasini@lonza.com


 

Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPTonline © 2004 The Pharmaceutical Technology Journal | Terms and Conditions | info@iptonline.com | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |